LUMINA trial tests manganese-based MRI contrast alternative
The phase 2/3 trial is evaluating mangaciclanol, GE HealthCare’s investigational manganese-based MRI contrast agent.
GE HealthCare has dosed the first patient in the international, multicenter phase 2/3 LUMINA trial of mangaciclanol, its investigational manganese-based MRI contrast agent. The patient was dosed at Mayo Clinic in Rochester, MN.
The agent has received FDA Fast Track designation for use in adults and pediatric patients ages 2 years and older. It is being studied for MRI to detect and visualize lesions with abnormal vascularity in the central nervous system and body.
GE HealthCare said mangaciclanol, if approved, could offer an alternative to gadolinium-based MRI contrast agents, the current standard of care.
MRI contrast agents are used to improve visualization of abnormal structures or lesions during imaging. The company said the investigational agent has shown comparable relaxivity to gadobutrol, a market-leading gadolinium-based agent.
Unlike gadolinium, manganese is an endogenous element that occurs naturally in the body, according to GE HealthCare. The firm said the macrocyclic structure of mangaciclanol is designed to reduce the possibility of retention.
The company also cited supply considerations. GE HealthCare said gadolinium supply is largely dependent on mining and processing infrastructure in China, while manganese is available from countries including South Africa, Australia, and Gabon.
Phase 1 results showed the agent was well tolerated in a first-in-human trial, with no serious adverse events, no dose-limiting toxicities, and no clinically relevant findings reported, the company said.
Mangaciclanol remains in clinical development and is not approved for use.
Company:GE HealthCare
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Pediatric ED imaging gaps persist by race and insurance status
A cohort study of 857,034 pediatric ED visits found that stronger hospital pediatric capability was not associated with narrower imaging-use differences by race, ethnicity, or insurance status.
Study finds wide variation in chest X-ray AI performance
A head-to-head study of 7 commercial AI devices found sensitivity ranged from 20.8% to 77.8% for lung cancer detection on chest X-rays.
MRI radiomics model predicts colorectal cancer subtype
The multicenter study found an MRI-based machine-learning radiomics score predicted CMS4 colorectal cancer and stratified recurrent metastasis risk.
Contrast tied to higher AKI risk in neonatal ICU study
The retrospective study found higher acute kidney injury rates in neonates exposed to iodinated contrast media, although most cases were stage 1.
Quantum BioPharma reports early PET tracer signal in MS study
The ongoing MGH study is evaluating [18F]3F4AP PET imaging for demyelinated neurons with intact axons in patients with multiple sclerosis.
Cochrane updates prostate cancer screening review
The updated review found PSA screening likely reduces prostate cancer deaths, but evidence remains unclear for newer screening strategies combining PSA, kallikrein testing, and MRI.
Stage 4 breast cancer diagnoses rise over decade
A cohort study of 761,471 people found de novo stage 4 breast cancer incidence increased by 1.2% per year from 2010 to 2021.
SIR backs genicular artery embolization for knee osteoarthritis
The Society of Interventional Radiology issued a position statement supporting genicular artery embolization for symptomatic knee osteoarthritis.
Fluoride, lead co-exposure linked to lower youth BMD
Researchers analyzed NHANES data from 2,378 U.S. children and adolescents who underwent DEXA scans from 2013 to 2016.
Stanford receives $3.9M ARPA-H grant for MR lymphangiography
Stanford Medicine received up to $3.9M from ARPA-H to advance MR lymphangiography. Andreas Loening, MD, PhD, will lead work on faster scans, lymphatic-specific contrast agents, and contrast-free flow assessment.
Bayer PET tracer meets cardiac amyloidosis endpoints
Bayer reported positive topline phase 3 REVEAL results for I-124 evuzamitide, an investigational PET/CT radiotracer for suspected cardiac amyloidosis. The study met its sensitivity and specificity endpoints.
14-minute MRx scan maps 20+ brain biomarkers without contrast
University of Illinois researchers developed multiplexed MRI to map more than 20 brain biomarkers in a single scan using standard clinical MRI systems.